Social participation and self-reported depression during the COVID-19 pandemic among older adults.

OBJECTIVES: The COVID-19 pandemic has increased depressive symptoms and disrupted activities that might typically mitigate depressive symptoms. Pandemic restrictions to social participation that supports well-being in older adults may contribute to worse mental health outcomes, but how participation relates to pandemic depressive symptoms is unclear. METHODS: Using longitudinal data from the nationally representative National Health and Aging Trends Study (N = 3181), we assessed whether older adults' pandemic depressive symptoms were associated with participation in paid work, volunteering, religious services, and other organized activities during the pandemic, as well as changes in participation in these activities compared to pre-pandemic engagement. RESULTS: Of participation during the pandemic, only attending religious services predicted pandemic depression, with religious attendance associated with higher risk of mild pandemic depressive symptoms. However, for changes in participation, stopping paid work during the pandemic predicted higher risk of moderate/severe pandemic depressive levels, while stopping attending religious services predicted lower risk of mild pandemic depression. CONCLUSION: This work demonstrates the importance of social participation for mental health and indicates what types of disruptions may reduce integration to increase older adults' vulnerability to depressive symptoms during a global pandemic.

A qualitative study of key stakeholders' perceived risks and benefits of psychiatric electroceutical interventions.

Amid a renewed interest in alternatives to psychotherapy and medication to treat depression, there is limited data as to how different stakeholders perceive of the risks and benefits of psychiatric electroceutical interventions (PEIs), including electroconvulsive therapy (ECT) and deep brain stimulation (DBS). To address this gap, we conducted 48 semi-structured interviews, including 16 psychiatrists, 16 persons diagnosed with depression, and 16 members of the general public. To provide a basis of comparison, we asked participants to also compare each modality to front-line therapies for depression and to neurosurgical procedures used for non-psychiatric conditions. Across all stakeholder groups, perceived memory loss was the most frequently mentioned potential risk with ECT. The most discussed benefits across all stakeholder groups were efficacy and quick response. Psychiatrists most often referenced effectiveness when discussing ECT, while patients and the public did so when discussing DBS. Taken as a whole, these data highlight stakeholders' contrasting perspectives on the risks and benefits of electroceuticals.